Inductive Bio received an award worth up to $21 million from ARPA‑H to lead DATAMAP, a consortium that will develop AI models predicting drug toxicity using data from human organoids, ex vivo tissues and microphysiological systems. Partners include Amgen, Cincinnati Children’s, Baylor College of Medicine and others; initial focus areas are drug‑induced liver injury and cardiotoxicity. The project aims to replace or reduce animal testing, produce human‑relevant safety predictions, and work with the FDA on regulatory applications of the resulting AI tools. If successful, the program could meaningfully reduce late‑stage safety attrition.